Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells

Journal of Microbiology and Biotechnology

Volumn 24, Issue 7, 2014, Pages 914-920

  Zhao, Qing ^a   Wu, Cheng Zhu ^a   Kyoung Lee, Jae ^b   Zhao, Su Rong ^a   Li, Hong Mei ^a   Huo, Qiang ^a   Ma, Tao ^a   Zhang, Jin ^a   Hong, Young Soo ^b   Liu, Hao ^a  

^a BENGBU MEDICAL COLLEGE   (China)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

17 demethoxy reblastatin; Anticancer effect; Hsp90; TNBC

Indexed keywords

17 DEMETHOXY REBLASTATIN; ADENOSINE TRIPHOSPHATASE; GELATINASE B; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEINASE; RIP1 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG PURITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MDA MB 231 CELL LINE; TRIPLE NEGATIVE BREAST CANCER; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PHYSIOLOGICAL PROCESSES; DOWN-REGULATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEOPLASM PROTEINS;

EID: 84904364428     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1311.11052     Document Type: Article

References (28)

1. Amend K, Hicks D, Ambrosone CB. 2006. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 66: 8327- 8330.
2. Baichwal VR, Baeuerle PA. 1997. Activate NF-κB or die? Curr. Biol. 7: R94-R96.
3. Bryan BB, Schnitt SJ, Collins LC. 2006. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol. 19: 617-621.
4. Cheng Q, Chang JT, Geradts J, Neckers LM, Haystead T, Spector NL, et al. 2012. Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer. Breast Cancer Res. 14: R62.
5. Chiosis G, Vilenchik M, Kim J, Solit D. 2004. Hsp90: the vulnerable chaperone. Drug Discov. Today 9: 881-888.
6. Da Silva VC, Ramos CH. 2012. The network interaction of the human cytosolic 90 kDa heat shock protein Hsp90: A target for cancer therapeutics. J. Proteomics 75: 2790-2802.
7. Groblewska M, Siewko M, Mroczko B, Szmitkowski M. 2012. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem. Cytobiol. 50: 12-19.
8. Han HZ. 2012. Research in progress of triple negative breast cancer molecular targeted therapy. Chinese Clin. Oncol. 17: 470-474.
9. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. 2008. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14: 7940-7946.
10. Hong YS, Lee D, Kim W, Jeong JK, Kim CG, Sohng JK, et al. 2004. Inactivation of the carbamoyltransferase gene refines post-polyketide synthase modification steps in the biosynthesis of the antitumor agent geldanamycin. J. Am. Chem. Soc. 126: 11142-11143.
11. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. 2003. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 69: 5898-5903.
12. Kim MS, Kwak HJ, Lee JW, Kim HJ, Park MJ, Park JB, et al. 2008. 17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion. Mol. Cancer Res. 6: 1657-1665.
13. Kim W, Lee D, Hong SS, Na Z, Shin JC, Roh SH, et al. 2009. Rational biosynthetic engineering for optimization of geldanamycin analogues. Chembiochem. 10: 1243-1251.
14. Kim W, Lee JS, Lee D, Cai XF, Shin JC, Lee K, et al. 2007. Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring. Chembiochem. 8: 1491-1494.
15. Messaoudi S, Peyrat JF, Brion JD, Alami M. 2011. Heat shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010. Expert Opin. Ther. Pat. 21: 1501-1542.
16. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
17. Mosser DD, Morimoto RI. 2004. Molecular chaperones and the stress of oncogenesis. Oncogene 23: 2907-2918.
18. Sankhala KK, Mita MM, Mita AC, Takimoto CH. 2011. Heat shock proteins: a potential anticancer target. Curr. Drug Targets 12: 2001-2008.
19. Shin JC, Zhu N, Lee DH, Kim WC, Lee K, Shen YM, et al. 2008. Characterization of tailoring genes involved in the modification of geldanamycin polyketide in Streptomyces hygroscopicus JCM4427. J. Microbiol. Biotechnol. 18: 1101-1108.
20. Whitesell L, Lindquist SL. 2005. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 5: 761-772.
21. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. 1994. Inhibition of heat shock protein 90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91: 8324-8328.
22. Wu CZ, Jang JH, Ahn JS, Hong YS. 2012. New geldanamycin analogs from Streptomyces hygroscopicus. J. Microbiol. Biotechnol. 22: 1478-1481.
23. Wu CZ, Jang JH, Woo M, Ahn JS, Kim SJ, Hong YS. 2012. Enzymatic glycosylation of nonbenzoquinone geldanamycin analogs via Bacillus UDP-glycosyltransferase. Appl. Environ. Microbiol. 78: 7680-7686.
24. Wrona IE, Gozman A, Taldone T, Chiosis G, Panek JS. 2010. Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90. J. Org. Chem. 75: 2820-2835.
25. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, et al. 2008. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 122: 2050-2056.
26. Xing H, Weng D, Chen G, Tao W, Zhu T, Yang X, et al. 2008. Activation of fibronectin/PI3K/Akt leads to chemoresistance to docetaxel by regulating surviving protein expression in ovarian and breast cancer. Cancer Lett. 261: 108-119.
27. Zhang H, Burrows F. 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 82: 488-499.
28. Zhao S, Ma W, Zhang M, Tang D, Shi Q, Xu S, et al. 2013. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med. Oncol. 30: 335.